156 related articles for article (PubMed ID: 15472186)
1. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis.
Dovio A; Perazzolo L; Osella G; Ventura M; Termine A; Milano E; Bertolotto A; Angeli A
J Clin Endocrinol Metab; 2004 Oct; 89(10):4923-8. PubMed ID: 15472186
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
3. High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption.
Dovio A; Perazzolo L; Saba L; Termine A; Capobianco M; Bertolotto A; Angeli A
Eur J Endocrinol; 2006 May; 154(5):745-51. PubMed ID: 16645023
[TBL] [Abstract][Full Text] [Related]
4. Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids.
Stepan JJ; Havrdová E; Týblová M; Horáková D; Tichá V; Nováková I; Zikán V
Clin Chim Acta; 2004 Oct; 348(1-2):147-54. PubMed ID: 15369748
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin.
Välimäki MJ; Kinnunen K; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Nieminen M
Osteoporos Int; 1999; 10(2):128-36. PubMed ID: 10501793
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
7. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
Grinspoon S; Baum H; Lee K; Anderson E; Herzog D; Klibanski A
J Clin Endocrinol Metab; 1996 Nov; 81(11):3864-70. PubMed ID: 8923830
[TBL] [Abstract][Full Text] [Related]
8. Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients.
Behan LA; Kelleher G; Hannon MJ; Brady JJ; Rogers B; Tormey W; Smith D; Thompson CJ; McKenna MJ; Agha A
Eur J Endocrinol; 2014 Jan; 170(1):141-50. PubMed ID: 24123094
[TBL] [Abstract][Full Text] [Related]
9. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin.
Välimäki MJ; Kinnunen K; Volin L; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Ruutu T
Bone Marrow Transplant; 1999 Feb; 23(4):355-61. PubMed ID: 10100579
[TBL] [Abstract][Full Text] [Related]
11. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.
Ueda M; Inaba M; Okuno S; Nagasue K; Kitatani K; Ishimura E; Shimizu M; Miki T; Kim M; Nishizawa Y
Am J Kidney Dis; 2002 Oct; 40(4):802-9. PubMed ID: 12324916
[TBL] [Abstract][Full Text] [Related]
13. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
[TBL] [Abstract][Full Text] [Related]
14. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
[TBL] [Abstract][Full Text] [Related]
15. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
16. Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis.
Olsson A; Oturai DB; Sørensen PS; Oturai PS; Oturai AB
Mult Scler; 2015 Oct; 21(12):1557-65. PubMed ID: 25623251
[TBL] [Abstract][Full Text] [Related]
17. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Lange U; Teichmann J; Müller-Ladner U; Strunk J
Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
[TBL] [Abstract][Full Text] [Related]
18. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
[TBL] [Abstract][Full Text] [Related]
19. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
20. Variance of spinal osteoporosis induced by dexamethasone and methylprednisolone and its associated mechanism.
Ren H; Liang D; Jiang X; Tang J; Cui J; Wei Q; Zhang S; Yao Z; Shen G; Lin S
Steroids; 2015 Oct; 102():65-75. PubMed ID: 26216207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
